Early trial results for the weight loss drug are positive. Novo Nordisk A/S Sponsored ADR Class B(NVO.US) is up over 2% in pre-market trading.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) has announced the full results of its experimental weight loss drug, Amycretin's early trials, causing the company's stock to rise in pre-market trading. As of the time of writing, Novo Nordisk A/S Sponsored ADR Class B is up 2.17% in pre-market trading, at $132.60. Results revealed at a European diabetes medical event held in Madrid suggest that the drug has potential comparable to the company's existing obesity products. Early data from the study has propelled Novo Nordisk A/S Sponsored ADR Class B's stock significantly in March. Aside from GLP-1, the company's intestinally-based obesity therapy Wegovy's sole target, Amycretin also targets a hormone called amylin, which affects hunger. Complete data from the phase I trial showed that patients who received the maximum dose of 2 X 50 mg of Amycretin experienced a weight loss of 13.1% at the end of the 12-week trial. In clinical studies, Novo Nordisk A/S Sponsored ADR Class B's FDA-approved weight loss therapy Wegovy helped patients lose about 6% of their weight after 12 weeks. Regarding side effects, there were 242 instances of mild to moderate side effects out of 60 participants. While there were no reports of serious side effects related to the amylin treatment, there was one severe but non-fatal adverse event. Martin Holst Lange, head of research and development at Novo Nordisk A/S Sponsored ADR Class B, stated: "What we've seen during the study is a 13.1% weight loss, with side effects comparable to what we typically see with intestinally-based insulin therapies, so mainly gastrointestinal side effects." Novo Nordisk A/S Sponsored ADR Class B is also developing another novel subcutaneous weight loss therapy called CagriSema. CagriSema is a compound consisting of semaglutide and another compound targeting amylin, cagrilintide, which has shown promising phase II data, helping patients lose around 16% of their weight after 32 weeks of treatment. Lange added: "The data I have seen so far suggests that amylin at least has the same weight loss potential as CagriSema."